Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 418

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 418
---
% of the gross proceeds raised in the Offering. The Company will also pay the
Placement Agent a cash management fee equal to 1.0% of the gross proceeds raised in the Offering, $5,000 for non-accountable expenses,
up to $50,000 for expenses of legal counsel and other out-of-pocket expenses and $10,000 for clearing fees all associated with the Offering.
The Company also issued the Placement Agent’s designees warrants (the “Placement Agent Warrants”) to purchase up to
60,000 Class A Ordinary Shares, at an exercise price equal to $2.50 per share. The Placement Agent Warrants are exercisable immediately
upon issuance on October 10, 2025 and expire on the earlier of 24 months from the effective date of a registration statement or October
10, 2030.

After deducting fees due to
the Placement Agent and offering expenses, the net proceeds from the Offering were approximately $1.7 million.

On July 14, 2025, the
Company entered into a Merger Agreement with DiamiR Biosciences Corp. encompassing a license agreement, management agreement and merger
agreement for the purchase and sale of DiamiR Biosciences Corp. (“DiamiR”, the “Target”). Pursuant to the merger
agreement, if completed, the Company would acquire all of the issued and outstanding capital stock of DiamiR, a private company incorporated
in Delaware, United States, from DiamiR’s shareholders through the issuance of shares of the Company’s common stock with
an estimated fair value of $32.8 million (the “Acquisition”). The Company considers completion of the merger agreement
to be probable.

The accompanying unaudited
pro forma condensed combined statement of financial position as of June 30, 2025 gives effect to both the Offering and the Acquisition
as if each had been consummated on June 30, 2025. The accompanying unaudited pro forma condensed combined statements of operations
for the year ended December 31, 2024 and for the six months ended June 30, 2025 give effect to both the Offering and the Acquisition
as if each had been consummated on January 1, 2024.

The accompanying unaudited
pro forma condensed combined statement of financial position as of June 30, 2025 combines the historical consolidated balance
sheet of Aptorum as of June 30, 2025 with the historical balance sheet of